



PerioTrap News
PerioTrap Pharmaceuticals, an i&i Prague Supported Start-up, Raises €3M Seed Round to Develop Selective Anti-infectives to Tackle Periodontitis
20.11.2020
Although periodontitis represents a widespread infectious disease affecting around 30% of the global population, there is no effective treatment for patients available, yet. PerioTrap Pharmaceuticals, a Fraunhofer IZI spin-off, has…
PerioTrap Pharmaceuticals, an i&i Prague Supported Start-up, Raises €3M Seed Round to Develop Selective Anti-infectives to Tackle Periodontitis
20.11.2020Although periodontitis represents a widespread infectious disease affecting around 30% of the global population, there is no effective treatment for patients available, yet. PerioTrap Pharmaceuticals, a Fraunhofer IZI spin-off, has…


LAM-X a.s. News
LAM-X, a.s. won the 2020 EIT Health #MedTech Bootcamp final #Pitch Event
18.1.2021
i&i Prague supported start-up, LAM-X, a.s., become a winner of the 2020 EIT Health…
Czech anti-covid19 #hackathon won by two i&i Prague accelerated projects
25.6.2020
Virtual #hackathon was a national challenge for all Czech scientists, companies, students and science-enthusiasts with a simple goal: gather the best Czech bio-technologies to fight COVID-19 crisis.
LAM-X – light-activated nanomaterials for face-masks and respirators
12.5.2020
LAM-X a.s. is the newest company established in cooperation with i&i Prague. It develops light-activated nanomaterials which provide protection from bacteria, viruses and other pathogens. The lead product is a…
LAM-X a.s. is collaborating with TUL to develop active nanofilters against COVID-19
7.5.2020
During COVID-19 crisis we embrace our startups to answer current questions and solve present problems. Our the most recently established startup – LAM-X, a.s. – is not an exception. LAM-X…
LAM-X: the newest spin-off company accelerated by i&i Prague in Czech Media
24.2.2020
Founding of LAM-X, a.s., the newest company accelerated by i&i Prague and Charles University Innovations Prague, s.r.o. was met with both interest and positive feedback from Czech national media.
LAM-X: revolutionary wound-treating nanomaterials
21.2.2020
Congratuations to LAM-X, a.s. – the newest company launched by i&i Prague! Story of LAM-X technology is a perfect example of our work in i&i…
LAM-X, a.s. won the 2020 EIT Health #MedTech Bootcamp final #Pitch Event
18.1.2021i&i Prague supported start-up, LAM-X, a.s., become a winner of the 2020 EIT Health…
Czech anti-covid19 #hackathon won by two i&i Prague accelerated projects
25.6.2020Virtual #hackathon was a national challenge for all Czech scientists, companies, students and science-enthusiasts with a simple goal: gather the best Czech bio-technologies to fight COVID-19 crisis.
LAM-X – light-activated nanomaterials for face-masks and respirators
12.5.2020LAM-X a.s. is the newest company established in cooperation with i&i Prague. It develops light-activated nanomaterials which provide protection from bacteria, viruses and other pathogens. The lead product is a…
LAM-X a.s. is collaborating with TUL to develop active nanofilters against COVID-19
7.5.2020During COVID-19 crisis we embrace our startups to answer current questions and solve present problems. Our the most recently established startup – LAM-X, a.s. – is not an exception. LAM-X…
LAM-X: the newest spin-off company accelerated by i&i Prague in Czech Media
24.2.2020Founding of LAM-X, a.s., the newest company accelerated by i&i Prague and Charles University Innovations Prague, s.r.o. was met with both interest and positive feedback from Czech national media.
LAM-X: revolutionary wound-treating nanomaterials
21.2.2020Congratuations to LAM-X, a.s. – the newest company launched by i&i Prague! Story of LAM-X technology is a perfect example of our work in i&i…

Dracen Pharmaceuticals, Inc. News
Dracen Pharmaceuticals Announces the Initiation of First-in-human Study of DRP-104 in Adult Patients With Advanced Solid Tumors!
13.10.2020
Pavel Majer, ÚOCHB Dracen Pharmaceuticals, Inc. has announced the start of a clinical trial of DRP-104, an anti-cancer substance developed by the team of Pavel Majer at IOCB Prague…
DRACEN Pharmaceuticals – Novel glutamine antagonist as anticancer therapies
12.5.2020
One of the first project i&i Prague participated in is Dracen Pharmaceuticals. Dracen itself started as an international science team at the Institute of Organic Chemistry and Biochemistry (IOCB Prague)…
Dracen Pharmaceuticals Announces the Initiation of First-in-human Study of DRP-104 in Adult Patients With Advanced Solid Tumors!
13.10.2020Pavel Majer, ÚOCHB Dracen Pharmaceuticals, Inc. has announced the start of a clinical trial of DRP-104, an anti-cancer substance developed by the team of Pavel Majer at IOCB Prague…
DRACEN Pharmaceuticals – Novel glutamine antagonist as anticancer therapies
12.5.2020One of the first project i&i Prague participated in is Dracen Pharmaceuticals. Dracen itself started as an international science team at the Institute of Organic Chemistry and Biochemistry (IOCB Prague)…

Elphogene, s.r.o. News
Elphogene, s.r.o. received a TA CR grant for “Sample prep system and technology for cancer testing by liquid biopsy”!
21.9.2020
Elphogene, s.r.o., an i&i Prague supported start-up, just received grant from the Technology Agency of the Czech Republic (referred to as the “TA CR“) for the project “Sample prep system…
Elphogene: non-invasive screening of patients in advanced stages of cancer
12.5.2020
Elphogene s.r.o. is a Czech spin-off company that succeeds decades of intensive research performed at Genomac research centre as well as thanks to collaborations with leading oncology centres. Using their…
Elphogene – liquid biopsy assay for non-invasive monitoring of patients with colorectal cancer.
23.2.2020
Another one of successful projects supported by i&i Prague is the Prague-based biotechnological start-up Elphogene, Inc. Its oncoMonitor™, a liquid biopsy technology, was recently turned into…
Elphogene Technology in World Journal of Gastroenterology!
7.1.2020
Another great achievement for one of our projects! Prague-based biotechnological start-up Elphogene is a progressive, young company focused on monitoring of patients in advanced stages colorectal cancer. With an…
Elphogene, s.r.o. received a TA CR grant for “Sample prep system and technology for cancer testing by liquid biopsy”!
21.9.2020Elphogene, s.r.o., an i&i Prague supported start-up, just received grant from the Technology Agency of the Czech Republic (referred to as the “TA CR“) for the project “Sample prep system…
Elphogene: non-invasive screening of patients in advanced stages of cancer
12.5.2020Elphogene s.r.o. is a Czech spin-off company that succeeds decades of intensive research performed at Genomac research centre as well as thanks to collaborations with leading oncology centres. Using their…
Elphogene – liquid biopsy assay for non-invasive monitoring of patients with colorectal cancer.
23.2.2020Another one of successful projects supported by i&i Prague is the Prague-based biotechnological start-up Elphogene, Inc. Its oncoMonitor™, a liquid biopsy technology, was recently turned into…
Elphogene Technology in World Journal of Gastroenterology!
7.1.2020Another great achievement for one of our projects! Prague-based biotechnological start-up Elphogene is a progressive, young company focused on monitoring of patients in advanced stages colorectal cancer. With an…

RIOCATH Global, a.s. News
Prague startup RIOCATH had recently entered market with its world-unique catheter!
12.5.2020
RIOCATH Global, a company established in collaboration with IOCB Tech, has developed a revolutionary type of catheter based on world-unique technology applicable for all tubular medical devices. Since its birth…
Startup Riocath is among Hello Tomorrow’s top 500 stratups in the world
1.2.2019
i&i Prague is excited to announce one of its partners, Riocath, will be featured among the top 500 deep tech startups at Hello Tomorrow’s upcoming global summit!
Prague startup RIOCATH had recently entered market with its world-unique catheter!
12.5.2020RIOCATH Global, a company established in collaboration with IOCB Tech, has developed a revolutionary type of catheter based on world-unique technology applicable for all tubular medical devices. Since its birth…
Startup Riocath is among Hello Tomorrow’s top 500 stratups in the world
1.2.2019i&i Prague is excited to announce one of its partners, Riocath, will be featured among the top 500 deep tech startups at Hello Tomorrow’s upcoming global summit!
News
i&i Prague announces its first exit: DIANA Biotechnologies
21.2.2022Prague, 21 February 2022 – BTND a.s. has completed the buyout of DIANA Biotechnologies from the portfolio of biotech incubator i&i Prague. For i&i Prague, the transaction opens up new…
CasInvent Pharma receives the Neuron Award for excellent Technology Transfer
1.10.2021The laureates of the prestigious Neuron Awards in 2021 have been announced. Since 2009, the Neuron Endowment Fund has been rewarding the first-class Czech researchers for their…
i&i Prague supports the innovative start-up PEP-Therapy in their extension of the Series-A financing, totalling €5.4 million to progress the clinical development of the lead candidate PEP-010
10.9.2021PEP-Therapy, a biotechnology company developing cell penetrating peptides as targeted therapies for the treatment of cancers, announced today that it raised an additional €2.6 million ($3 million) in an extension…
Enantis, a Masaryk University spin-off company, concluded a license agreement for the production of stabilised growth factor FGF2.
29.1.2021After months of negotiations, we are delighted to announce that Enantis, one of i&i Prague´s first supported start-ups, has entered into a…
LAM-X, a.s. won the 2020 EIT Health #MedTech Bootcamp final #Pitch Event
18.1.2021i&i Prague supported start-up, LAM-X, a.s., become a winner of the 2020 EIT Health…